



Regulus Therapeutics Inc.  
Investor Relations Department  
10614 Science Center Dr  
San Diego, CA 92121  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: RGLS

Last Trade:	1.02
Trade Time:	4:00 PM ET Jun 26, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.90 - 5.35
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *microRNAs*. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced *microRNA* therapeutics pipeline complemented by a maturing *microMarkers*<sup>SM</sup> biomarkers platform and a rich intellectual property estate to retain its leadership in the *microRNA* field. Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting *microRNA*-122 for the tre... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- [Jun 13, 2017](#)  
[Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer](#)
- [Jun 12, 2017](#)  
[Regulus Announces Pipeline Updates and Advancements](#)
- [Jun 1, 2017](#)  
[Pascale Witz Joins Regulus Board of Directors](#)
- [May 4, 2017](#)  
[Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring](#)
- [Apr 27, 2017](#)  
[Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- [Mar 3, 2017](#)  
[Annual Report \(10-K\)](#)
- [Apr 28, 2017](#)  
[Proxy Statement \(DEF 14A\)](#)
- [May 5, 2017](#)  
[Quarterly Report \(10-Q\)](#)
- [Nov 2, 2016](#)  
[Quarterly Report \(10-Q\)](#)
- [Aug 3, 2016](#)  
[Quarterly Report \(10-Q\)](#)